Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are
several distinct histotypes of this malignancy characterized by specific molecular events and …

High-grade serous ovarian cancers have low survival rates because of their late
presentation with extensive peritoneal metastases and frequent chemoresistance, and …

Genome integrity is under constant insult from endogenous and exogenous sources. In
order to cope, eukaryotic cells have evolved an elaborate network of DNA repair that can …

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose)
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit the concept of
synthetic lethality and offer great promise in the treatment of tumors with deficiencies in …

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance
is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical …

Advanced and recurrent gynecological cancers lack effective treatment and have poor
prognosis. Besides, there is urgent need for conservative treatment for fertility protection of …

Ovarian cancer is the leading cause of gynecological cancer death. Improved understanding
of the biologic pathways and introduction of poly (ADP-ribose) polymerase inhibitors …

While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous
recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and …